This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Blood disease specialist Hemab Therapeutics and brain drug developer Seaport Therapeutics both priced initial public offerings on Thursday evening, hauling in a combined $556.4 million to fund the advancement of their respective drug therapies into late-stage clinical testing. Hemab raised $301.5 million in its offering, selling nearly 17 million shares at $1 ...